ERBB2 and prostate carcinoma: Other BiTEs in clinical trials for the treatment of solid neoplasms target carcinoembryonic antigen (CEA) for nonsmall-cell lung carcinoma (NSCLC), Delta-like Ligand 3 (DLL3) for small cell lung cancer, epidermal growth factor receptor variant iii (EGFRviii) for glioblastoma, epithelial cell adhesion molecule (EpCAM) for NSCLC, human epidermal growth factor receptor 2 (HER-2) for breast cancer, Mucin 16 (MUC16) for ovarian cancer, prostate-specific membrane antigen (PSMA) for prostate cancers, and the somatostatin receptor (SSTR2) for neuroendocrine tumors, among others [101,103].